Last reviewed · How we verify
fesoterodine 4mg
At a glance
| Generic name | fesoterodine 4mg |
|---|---|
| Also known as | Toviaz |
| Sponsor | University of Alberta |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy (PHASE4)
- A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment (PHASE2)
- Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI) (PHASE2)
- Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. (PHASE3)
- Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children (PHASE3)
- A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency (PHASE4)
- An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia (PHASE4)
- InSite for Over Active Bladder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fesoterodine 4mg CI brief — competitive landscape report
- fesoterodine 4mg updates RSS · CI watch RSS
- University of Alberta portfolio CI